Intellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients
15/6 16:50
Lonvo-z showed a 98% reduction in HAE attacks for 10 patients over three-year follow-up, demonstrating promising safety and efficacy....